Although still a clinical-stage biopharma company, Madrigal Pharmaceuticals, Inc. made an all-out showing at the American Association for the Study of Liver Disease annual meeting to establish its position as the leader in the NASH race – from sponsoring the wi-fi at the meeting and emblazoning its logo on many attendees’ hotel key cards to introducing a new chief commercialization officer and launching physician awareness efforts.
Madrigal has a 14 March US Food and Drug Administration action date for resmetirom (MDGL-3196), its thyroid hormone receptor beta (THRβ) agonist up for approval to treat non-alcoholic steatohepatitis (NASH) with advanced fibrosis
Key Takeaways
-
Madrigal presented an air of confidence at 2023’s Liver Meeting that resmetirom is likely to be the first approved NASH drug, and used the conference to make a splash before prescribers.
-
The THRβ agonist has a March FDA action date and could become an approved therapy to treat NASH patients with advanced fibrosis after Intercept was expected to reach market first in 2020
